Rami Bechara

Rami Bechara

Auto-generated profile, based on publicly available information

Rami Bechara

Université Paris-Saclay, INSERM, CEA, Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184)

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
XLXiaoxia Li
Xiaoxia Li
RBRami Bechara
Rami Bechara
JZJunjie Zhao
Junjie Zhao
MMMandy J. McGeachy
Mandy J. McGeachy
SGSarah Gaffen
Sarah Gaffen

5 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RBRami Bechara
Rami Bechara
MMMandy J. McGeachy
Mandy J. McGeachy
SGSarah Gaffen
Sarah Gaffen
IL-17 was discovered nearly 30 yr ago, but it has only been recently appreciated that a key function of this cytokine is to orchestrate cellular and organismal metabolism. Indeed, metabolic regulation is integrated into both the physiological and the pathogenic aspects of IL-17 responses. Thus, understanding the interplay between IL-17 and downstream metabolic processes could ultimately inform therapeutic opportunities for diseases involving IL-17, including some not traditionally linked to this cytokine pathway. Here, we discuss the emerging pathophysiological roles of IL-17 related to cellular and organismal metabolism, including metabolic regulation of IL-17 signal transduction.

29 July 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RBRami Bechara
Rami Bechara
NANilesh Amatya
Nilesh Amatya
RBRachel D. Bailey
Rachel D. Bailey
YLYang Li
Yang Li
FAFelix E. Y. Aggor
Felix E. Y. Aggor
SGSarah Gaffen
Sarah Gaffen
Excessive cytokine activity underlies many autoimmune conditions, particularly through the interleukin-17 (IL-17) and tumor necrosis factor–α (TNFα) signaling axis. Both cytokines activate nuclear factor κB, but appropriate induction of downstream effector genes requires coordinated activation of other transcription factors, notably, CCAAT/enhancer binding proteins (C/EBPs). Here, we demonstrate the unexpected involvement of a posttranscriptional “epitranscriptomic” mRNA modification [N6-methyladenosine (m6A)] in regulating C/EBPβ and C/EBPδ in response to IL-17A, as well as IL-17F and TNFα. Prompted by the observation that C/EBPβ/δ-encoding transcripts contain m6A consensus sites, we show that Cebpd and Cebpb mRNAs are subject to m6A modification. Induction of C/EBPs is enhanced by an m6A methylase “writer” and suppressed by a demethylase “eraser.” The only m6A “reader” found to be involved in this pathway was IGF2BP2 (IMP2), and IMP2 occupancy of Cebpd and Cebpb mRNA was enhanced by m6A modification. IMP2 facilitated IL-17–mediated Cebpd mRNA stabilization and promoted translation of C/EBPβ/δ in response to IL-17A, IL-17F, and TNFα. RNA sequencing revealed transcriptome-wide IL-17–induced transcripts that are IMP2 influenced, and RNA immunoprecipitation sequencing identified the subset of mRNAs that are directly occupied by IMP2, which included Cebpb and Cebpd. Lipocalin-2 (Lcn2), a hallmark of autoimmune kidney injury, was strongly dependent on IL-17, IMP2, and C/EBPβ/δ. Imp2−/− mice were resistant to autoantibody-induced glomerulonephritis (AGN), showing impaired renal expression of C/EBPs and Lcn2. Moreover, IMP2 deletion initiated only after AGN onset ameliorated disease. Thus, posttranscriptional regulation of C/EBPs through m6A/IMP2 represents a previously unidentified paradigm of cytokine-driven autoimmune inflammation.

1 October 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RBRami Bechara
Rami Bechara
DADiane Antonios
Diane Antonios
HAHayat Azouri
Hayat Azouri
MPMarc Pallardy
Marc Pallardy

22 January 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
MAM. E. Azoury
M. E. Azoury
LFL. Filì
L. Filì
RBR. Bechara
R. Bechara
NSN. Scornet
N. Scornet
LCL. de Chaisemartin
L. de Chaisemartin
MPM. Pallardy
M. Pallardy

4 May 2017 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
MPMarc Pallardy
Marc Pallardy
RBRami Bechara
Rami Bechara
Hypersensitivity reaction or allergy, initially perceived as a secondary disorder, is now believed to be a major public health concern. For instance, contact dermatitis is a type IV delayed-type hypersensitivity reaction to skin allergens. An estimated 15%–20% of the general population has acquired contact allergy. To maintain immune tolerance, our immune system needs to differentiate between harmful non-self and innocuous non-self. Living organisms have developed during their evolution a set of biological mechanisms to protect them from the “outside”: physical barrier, inflammation, cell-based mechanisms, metabolism and elimination, and biochemical pathways such as glutathione. The innate and adaptive immune systems are also involved in the protection from the “outside” by mounting specific or non-specific responses leading to the clearance of dangerous triggers such as viruses, bacteria, or parasites. In the case of chemical or drug allergy, is our immune system clearing the danger resulting from environmental exposure to these harmful chemicals with a true immune response? Is the immune system then triggered specifically for its role: clearing a specific problem? Alternatively, should we perceive chemical or drug hypersensitivity as an accident with uncontrolled consequences leading to immunopathology?